Invesaro

Stocks Comparison

Innospec vs Ingevity: revenue, profit, margins and growth compared

Innospec brought in $1.8B of revenue in fiscal 2025, Ingevity $1.2B in fiscal 2025. Revenue changed by -3.7% at Innospec and -2.7% at Ingevity on the year before, so Ingevity grew faster. Innospec kept 6.6% of its revenue as net profit, Ingevity -14.3%. Free cash flow was $88M at Innospec and $273.5M at Ingevity.

Side by side, latest fiscal year

IOSPNGVT
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$1.8B$1.2B
Revenue growth-3.7%-2.7%
Net income$116.6M-$167.1M
Net margin6.6%-14.3%
Free cash flow$88M$273.5M
Free cash flow margin4.9%23.4%
Earnings per share (diluted)$4.67-$4.61
Cash$292.5M$78.1M
Debtn/a$47.1M
Price to earnings21.1n/a
Market value$2.4B$2.5B
Dividend yield1.73%n/a
Rank by revenue in sector#231 of 451 · Industrials#259 of 451 · Industrials

Over the years

Revenue
IOSP FY2018: $1.5BIOSP FY2019: $1.5BIOSP FY2020: $1.2BIOSP FY2021: $1.5BIOSP FY2022: $2BIOSP FY2023: $1.9BIOSP FY2024: $1.8BIOSP FY2025: $1.8BNGVT FY2018: $1.1BNGVT FY2019: $1.3BNGVT FY2020: $1.2BNGVT FY2021: $1.4BNGVT FY2022: $1.7BNGVT FY2023: $1.2BNGVT FY2024: $1.2BNGVT FY2025: $1.2BFY18FY19FY20FY21FY22FY23FY24FY25
IOSP $1.8BNGVT $1.2B
Net income
IOSP FY2018: $85MIOSP FY2019: $112.2MIOSP FY2020: $28.7MIOSP FY2021: $93.1MIOSP FY2022: $133MIOSP FY2023: $139.1MIOSP FY2024: $35.6MIOSP FY2025: $116.6MNGVT FY2018: $169.1MNGVT FY2019: $183.7MNGVT FY2020: $181.4MNGVT FY2021: $118.1MNGVT FY2022: $211.6MNGVT FY2023: -$5.4MNGVT FY2024: -$430.3MNGVT FY2025: -$167.1MFY18FY19FY20FY21FY22FY23FY24FY25
IOSP $116.6MNGVT -$167.1M
Net margin
IOSP FY2018: 5.8%IOSP FY2019: 7.4%IOSP FY2020: 2.4%IOSP FY2021: 6.3%IOSP FY2022: 6.8%IOSP FY2023: 7.1%IOSP FY2024: 1.9%IOSP FY2025: 6.6%NGVT FY2018: 14.9%NGVT FY2019: 14.2%NGVT FY2020: 14.9%NGVT FY2021: 8.5%NGVT FY2022: 12.7%NGVT FY2023: -0.4%NGVT FY2024: -35.9%NGVT FY2025: -14.3%FY18FY19FY20FY21FY22FY23FY24FY25
IOSP 6.6%NGVT -14.3%
Revenue growth
IOSP FY2019: +2.5%IOSP FY2020: -21.2%IOSP FY2021: +24.3%IOSP FY2022: +32.4%IOSP FY2023: -0.8%IOSP FY2024: -5.3%IOSP FY2025: -3.7%NGVT FY2019: +14.1%NGVT FY2020: -5.9%NGVT FY2021: +14.4%NGVT FY2022: +19.9%NGVT FY2023: -27.1%NGVT FY2024: -1.3%NGVT FY2025: -2.7%FY19FY20FY21FY22FY23FY24FY25
IOSP -3.7%NGVT -2.7%
Free cash flow
IOSP FY2018: $76MIOSP FY2019: $131.7MIOSP FY2020: $116.2MIOSP FY2021: $54.1MIOSP FY2022: $42.1MIOSP FY2023: $145.2MIOSP FY2024: $143.1MIOSP FY2025: $88MNGVT FY2018: $158.1MNGVT FY2019: $160.9MNGVT FY2020: $270.3MNGVT FY2021: $189.5MNGVT FY2022: $170.9MNGVT FY2023: $95.3MNGVT FY2024: $51MNGVT FY2025: $273.5MFY18FY19FY20FY21FY22FY23FY24FY25
IOSP $88MNGVT $273.5M

Fiscal years as each company reports them; the two may end in different months.

Questions about Innospec and Ingevity

Which is bigger by revenue, Innospec or Ingevity?

Innospec is bigger by revenue: $1.8B in fiscal 2025, against $1.2B for Ingevity in fiscal 2025.

Which keeps more of its revenue as profit, Innospec or Ingevity?

Innospec had a net margin of 6.6% in fiscal 2025; Ingevity had -14.3% in fiscal 2025.

Which grew revenue faster, Innospec or Ingevity?

In their latest fiscal years revenue changed by -3.7% at Innospec and -2.7% at Ingevity.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies